Holdings
PSP Research LLC
As of Sep 30, 2026, PSP Research LLC reported 40 positions worth US$145M. Largest: iShares 0-3 Month Treasury Bond ETF, State Street SPDR S&P Biotech ETF and Sera Prognostics, Inc. What it bought and sold, with each filing.
Holdings
- Positions
- 40
- Value as reported
- US$145M
- Holdings as of
- Sep 30, 2026
- Last filed
- Oct 21, 2026
| Company | Shares | Value as reported | % of company | % of portfolio | Change | As of |
|---|---|---|---|---|---|---|
| iShares 0-3 Month Treasury Bond ETF NYSE:SGOV | 700K | US$70.5M | 48.3% | New | Sep 30, 2026 | |
| State Street SPDR S&P Biotech ETF AMEX:XBI | 387K | US$60.9M | 41.8% | New | Sep 30, 2026 | |
| Sera Prognostics, Inc. NASDAQ:SERA | 2.4M | US$5.01M | 6.2% | 3.4% | New | Sep 30, 2026 |
| Halozyme Therapeutics, Inc. NASDAQ:HALO | 3,000 | US$331K | 0.23% | −4,000 | Sep 30, 2026 | |
| Madrigal Pharmaceuticals, Inc. NASDAQ:MDGL | 600 | US$302K | <0.01% | 0.21% | No change | Sep 30, 2026 |
| Exelixis, Inc. NASDAQ:EXEL | 5,000 | US$292K | 0.20% | −3,000 | Sep 30, 2026 | |
| argenx SE EURONEXT:ARGX | 300 | US$288K | 0.20% | −341 | Sep 30, 2026 | |
| Nurix Therapeutics, Inc. NASDAQ:NRIX | 12,000 | US$285K | 0.20% | −13,000 | Sep 30, 2026 | |
| TG Therapeutics, Inc. NASDAQ:TGTX | 5,000 | US$279K | <0.01% | 0.19% | −5,000 | Sep 30, 2026 |
| Tarsus Pharmaceuticals, Inc. NASDAQ:TARS | 3,500 | US$275K | 0.19% | −3,500 | Sep 30, 2026 | |
| Harmony Biosciences Holdings, Inc. NASDAQ:HRMY | 7,000 | US$275K | 0.01% | 0.19% | −3,000 | Sep 30, 2026 |
| Arcutis Biotherapeutics, Inc. NASDAQ:ARQT | 10,000 | US$264K | 0.18% | −9,700 | Sep 30, 2026 | |
| Supernus Pharmaceuticals, Inc. NASDAQ:SUPN | 6,000 | US$258K | 0.01% | 0.18% | No change | Sep 30, 2026 |
| Immunome, Inc. NASDAQ:IMNM | 12,000 | US$258K | 0.18% | −6,000 | Sep 30, 2026 | |
| Neurocrine Biosciences, Inc. NASDAQ:NBIX | 1,800 | US$255K | 0.18% | −1,200 | Sep 30, 2026 | |
| Oruka Therapeutics, Inc. NASDAQ:ORKA | 3,000 | US$250K | 0.17% | No change | Sep 30, 2026 | |
| Tango Therapeutics, Inc. NASDAQ:TNGX | 10,000 | US$250K | 0.17% | No change | Sep 30, 2026 | |
| Definium Therapeutics, Inc. NASDAQ:DFTX | 6,500 | US$247K | <0.01% | 0.17% | −3,500 | Sep 30, 2026 |
| Revolution Medicines, Inc. NASDAQ:RVMD | 1,200 | US$246K | <0.01% | 0.17% | No change | Sep 30, 2026 |
| Aurinia Pharmaceuticals Inc NASDAQ:AUPH | 15,000 | US$243K | 0.01% | 0.17% | −15,000 | Sep 30, 2026 |
| Incyte Corporation NASDAQ:INCY | 2,000 | US$243K | <0.01% | 0.17% | −3,300 | Sep 30, 2026 |
| Intellia Therapeutics, Inc. NASDAQ:NTLA | 20,000 | US$241K | 0.01% | 0.17% | No change | Sep 30, 2026 |
| Immunovant, Inc. NASDAQ:IMVT | 7,000 | US$236K | <0.01% | 0.16% | −6,000 | Sep 30, 2026 |
| Stoke Therapeutics, Inc. NASDAQ:STOK | 9,000 | US$234K | 0.16% | −3,000 | Sep 30, 2026 | |
| Krystal Biotech, Inc. NASDAQ:KRYS | 692 | US$230K | <0.01% | 0.16% | No change | Sep 30, 2026 |
| Syndax Pharmaceuticals, Inc. NASDAQ:SNDX | 12,000 | US$226K | 0.15% | −8,000 | Sep 30, 2026 | |
| Kymera Therapeutics, Inc. NASDAQ:KYMR | 2,000 | US$224K | 0.15% | −2,000 | Sep 30, 2026 | |
| Dianthus Therapeutics, Inc. NASDAQ:DNTH | 2,500 | US$220K | 0.15% | No change | Sep 30, 2026 | |
| Trevi Therapeutics, Inc. NASDAQ:TRVI | 15,000 | US$215K | 0.15% | −15,000 | Sep 30, 2026 | |
| Mirum Pharmaceuticals, Inc. NASDAQ:MIRM | 2,500 | US$214K | 0.15% | No change | Sep 30, 2026 | |
| Immunocore Holdings plc NASDAQ:IMCR | 7,000 | US$212K | 0.01% | 0.15% | New | Sep 30, 2026 |
| Protagonist Therapeutics, Inc. NASDAQ:PTGX | 1,500 | US$211K | 0.14% | −1,500 | Sep 30, 2026 | |
| Edgewise Therapeutics, Inc. NASDAQ:EWTX | 5,000 | US$203K | 0.14% | No change | Sep 30, 2026 | |
| ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | 13,000 | US$175K | 0.12% | No change | Sep 30, 2026 | |
| Dyne Therapeutics, Inc. NASDAQ:DYN | 10,000 | US$161K | 0.11% | −10,000 | Sep 30, 2026 | |
| COMPASS Pathways Plc NASDAQ:CMPS | 10,000 | US$124K | <0.01% | 0.09% | New | Sep 30, 2026 |
| Ocular Therapeutix, Inc. NASDAQ:OCUL | 15,000 | US$115K | <0.01% | 0.08% | No change | Sep 30, 2026 |
| CytomX Therapeutics, Inc. NASDAQ:CTMX | 39,400 | US$107K | 0.02% | 0.07% | No change | Sep 30, 2026 |
| Ardelyx, Inc. NASDAQ:ARDX | 30,000 | US$103K | 0.01% | 0.07% | −30,000 | Sep 30, 2026 |
| Olema Pharmaceuticals, Inc. NASDAQ:OLMA | 10,000 | US$86,400 | 0.06% | No change | Sep 30, 2026 |